NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by Axa S.A.

AXA S.A. lowered its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 19.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 278,266 shares of the company's stock after selling 66,387 shares during the period. AXA S.A. owned approximately 0.30% of NewAmsterdam Pharma worth $7,151,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in shares of NewAmsterdam Pharma by 176.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company's stock worth $371,000 after acquiring an additional 14,280 shares during the last quarter. Legal & General Group Plc boosted its position in shares of NewAmsterdam Pharma by 24.8% during the fourth quarter. Legal & General Group Plc now owns 22,946 shares of the company's stock worth $590,000 after buying an additional 4,556 shares during the period. American Century Companies Inc. acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at $8,907,000. Geode Capital Management LLC grew its stake in shares of NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company's stock valued at $1,433,000 after buying an additional 1,399 shares in the last quarter. Finally, Swiss National Bank lifted its stake in NewAmsterdam Pharma by 105.1% during the 4th quarter. Swiss National Bank now owns 72,000 shares of the company's stock worth $1,850,000 after acquiring an additional 36,900 shares in the last quarter. Hedge funds and other institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Trading Down 4.7 %

Shares of NAMS stock traded down $0.90 on Friday, reaching $18.37. 974,266 shares of the stock were exchanged, compared to its average volume of 620,020. The company has a market capitalization of $2.02 billion, a price-to-earnings ratio of -7.07 and a beta of 0.01. The business's 50 day moving average price is $19.52 and its 200 day moving average price is $21.22. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The firm had revenue of $2.98 million during the quarter, compared to analyst estimates of $1.46 million. Equities research analysts forecast that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Insider Transactions at NewAmsterdam Pharma

In related news, Director James N. Topper purchased 1,135 shares of NewAmsterdam Pharma stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average cost of $22.49 per share, with a total value of $25,526.15. Following the completion of the transaction, the director now directly owns 3,013,569 shares in the company, valued at approximately $67,775,166.81. The trade was a 0.04 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Louise Frederika Kooij sold 150,000 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the transaction, the chief accounting officer now directly owns 15,000 shares in the company, valued at approximately $305,550. The trade was a 90.91 % decrease in their position. The disclosure for this sale can be found here. Insiders own 19.50% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on NAMS shares. UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. Needham & Company LLC cut their target price on shares of NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating on the stock in a research note on Thursday. Royal Bank of Canada reissued an "outperform" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Scotiabank upped their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Thursday, February 27th. Finally, HC Wainwright reiterated a "buy" rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $43.00.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.